Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
November 25, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 21, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
November 05, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Sloane & Company Expands its Healthcare Practice with the Appointment of Managing Director Leslie Wheeler
October 15, 2024 08:00 ET
|
Sloane & Company
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Sloane & Company, a strategic communications firm at the intersection of valuation and reputation, announces the appointment of Leslie Wheeler as a...
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting